Clinical Trial Update: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing momelotinib to danazol in symptomatic and anemic myelofibrosis has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Danazol (danazol)
• Momelotinib (momelotinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Status: COMPLETED | Results posted: 2022-12-22